Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

Employers and benefits advisors are facing a growing challenge: How to offer access to these high-demand, life-changing ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Last year, GLP-1s dominated many employer conversations as demand surged and pressure mounted from employees clamoring for ...

Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, particularly in patients with type 2 diabetes, when combined with ...

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

A 2022 study on Wegovy, for example, found that people regained two-thirds of the weight they’d lost a year after stopping the medication. Weight regain can also happen after stopping other GLP ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...